Thank you @JAMANetworkOpen for the invitation to pen the editorial in response to Kar et al, on early-onset non-small cell #lung #cancer #lcsm 🫁 🙏 Grateful to write this with Drs @Jonas_Willmann and @IyengarPuneeth 🔗 https://t.co/igErqiccBI

📢Come join us! Excellent line-up of speakers and early-career networking sessions! #MHNCS26 👇Schedule of events below: https://t.co/v7q3KNYEcN @AHNSinfo @ASCO @sitcancer @hncalliance @oralcancerfnd @spohnc_1

MSK computer scientists and radiation oncologists have developed #AI models to make #radiation therapy safer and more effective — helping to spare healthy tissue and make decisions about needed changes to treatment faster. Learn more: https://t.co/rtC5iNXI0f

4/4 Deferring adj RT based on post-op TTMV-HPV DNA testing led to a high rate of disease recurrence. More work is needed to guide use of HPV ctDNA as an integral biomarker. Grateful to our patients, MSKCC HN DMT, and co-PI’s Marc Cohen, Eric Sherman, @imrtlee

3/4 Active surveillance resulted in early cohort closure (predefined stopping rule) – with 3/12 patients developing gross recurrence 6 months post-op. Radiographic recurrence was not preceded by a positive TTMV-HPV DNA score.

🧵1/4 PATH study(Cohort A) out in @IJROBP – Our trial asks whether undetectable post-operative HPV ctDNA can select OPC candidates for adj RT omission and found high rates of disease recurrence #radonc #hncsm https://t.co/1KLj9qTK4M

BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”

How often can one say that they had hosted a talk with a Nobel prize winner! Was so excited when I woke up to this news that Prof Shimon Sakaguchi had won this year #NobelPrize2025 for #Medicine ! Despite such nobility (pun intended), such a humble individual who spoke on

👋Fantastic work by @treechairusame @imrtlee @MSK_RadOnc @MSKCancerCenter partial larynx IMRT. ➡️63 Gy/28 fx Tis-1N0 ➡️65.25 Gy/29fx T2N0 Excellent LRC. No contra cord failure.

I am thrilled to share our recent HN research publication in https://t.co/brDvTSUIrN: “Partial vs Whole Laryngeal RT for T1–2N0M0/Tis Laryngeal Carcinoma.” Thank you Dr. Lee @imrtlee and HN team @EChrisDee, for all of your support.

So proud of my friend and collaborator Dr Teeradon @treechairusame who presented adaptive head and neck RT work at @ASTRO_org 🙏🙏 @imrtlee and @MSK_RadOnc and physics team for this cool work!

This week during #ASTRO2025, we hosted our second PULSAR Consortium Meeting. Thank you to everyone who joined us for this successful event! A special thank you to our moderator, Dr. @PercyLeeMD, and our speakers: Drs. @BobTimmermanMD, @AsalRahimiMD, @imrtlee, and Zhen Zhang.

At #ASTRO25, Nancy Lee, MD, (@imrtlee @MSKCancerCenter) shares findings of the KEYNOTE-689 study, the addition of neoadjuvant and adjuvant (starting concurrently with postoperative radiotherapy [PORT] ± cisplatin) pembro to SOC significantly improved event-free survival (EFS) vs

I think we need to reserve judgement and final analysis until seeing all of the papers from these trials…. … but are these results really so different? - In the US trial, more IMRT patients (40% vs. 27% = 13% difference) received g-tubes. - In the UK trial, more IMRT patients

#ASTRO2025 #Plenary Congrats to TORPEDO investigators led by @DrDThomson Excellent discussion by @VinitaTakiar Lots to chew upon but while not the Main endpoint, there were differences at post- and 6w post-RT in favour of #Protons #IMPT Relevant to patients? 🤔

🚨TOROEDO trial - superbly executed with uniform RT plan QA/no crossover. No difference in either endpoints. What’s next? Refine the strategy. Technology is a means to an end. Reduce volume and dose (gross/elective) with biology based therapy selection. @ASTRO_org #astro25

So proud of Yingzhi Wu, from the @MSKCancerCenter @MSK_RadOnc head and neck service, who presented our work on PEG rates among patients with head and neck cancers @imrtlee @xrtGenomics @seanmmcbride @CJTsaiMDPhD @FanYangMD @ASTRO_org #ASTRO2025

Honored to train at ⁦@MSKCancerCenter⁩ #radonc alongside experts, change makers, and good people 🤩 #ASTRO2025 ⁦@ASTRO_org⁩ ⁦@DanielGorovets⁩ ⁦@seanmmcbride⁩ ⁦@KaitlynLapen⁩ ⁦@MSK_RadOnc⁩ Thank you to Melissa and Amelia for setting this up

It was such a pleasure to read the results of this juicy and terrific randomized trial of postop RT dose de-escalation for HPV+ OPSCC from @DanielMaMD and colleagues at @MayoRadOnc. The field has been waiting for the formal results, and this paper does not disappoint.

Reviewing papers is prob the most UnderValued academic activity that is yet crucial to upkeep the standards of transparency and robustness of research and journals So it is a very “neat” gesture by @lachiemcd @sueyom @ASTRO_org @IJROBP @ElsevierConnect to receive this simple